There is provided a CRF receptor antagonist comprising a compound of the formula (I): wherein, ring A is a 5-membered ring represented by the formula (A'): wherein X is a carbon and X.sup.1 is an oxygen, a sulfur or --NR.sup.5--, or formula (A''): wherein X is a nitrogen and R.sup.6 is an optionally substituted hydrocarbyl, R.sup.1 is an amino substituted by two optionally substituted hydrocarbyl groups, R.sup.2 is an phenyl, Y.sup.1 is CR.sup.3a or a nitrogen, y.sup.2 is CR.sup.3b or a nitrogen and Y.sup.3 is CR.sup.3c or a nitrogen, provided that one or less of Y.sup.1, Y.sup.2, and Y.sup.3 is nitrogen, W is a bond, --(CH.sub.2)n-, and Z is a bond, --NR.sup.4--, etc.; or a salt thereof or a prodrug thereof.